Groundbreaking Bowel Cancer Trial Had Zero Relapses for Patients After 33 Months

A small but substantial tweak to the treatment regime of bowel cancer demonstrated remarkable improvements in survival almost 3 years after surgery. Changing the kind of drug and the delivery window showed substantial improvements over the previous pairing, and build on earlier results showing that the drug led to major tumor shrinkage in patients